NCT02189161已完成不适用
A Safety and Tolerability Trial of Circumferential Anal Canal Radiofrequency Ablation For Anal Intraepithelial Neoplasia Using the Barrx™ Ablation System
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Related Adverse Events
研究概览
简要总结
Assess the safety, feasibility, and patient tolerability of circumferential radiofrequency ablation (RFA) to the anal canal for patients with anal intraepithelial neoplasia (AIN). Patients will have AIN with high grade squamous intraepithelial lesions (HSIL) and the RFA will be applied using the Barrx™ Ablation System.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Candidates for this study must meet all of the following criteria:
- •Age 18-75 years
- •HRA 2 to 8 weeks prior to the 0 month RFA visit yielding one or more flat, non-condylomatous biopsy-proven HSILs that are
- •Located entirely within the eligible treatment zone AND
- •Contiguous with the squamocolumnar junction
- •Eligible treatment zone (ETZ) is defined as
- •3 cm above the dentate line to the anocutaneous line AND
- •Full anorectal circumference
- •If female of child-bearing age, negative pregnancy test within 8 weeks of the 0 month RFA visit and declared intent to remain on birth control throughout the trial, or declaration of infertility defined as subject report of status as post-menopausal or surgically sterile (status post hysterectomy or tubal ligation).
- •If HIV positive
- •HIV positive on antiretroviral therapy for at least 3 months with laboratory blood work within 12 weeks prior to the 0 month visit demonstrating viral load < 50
- •CD4 count ≥ 250/mm3
- •ANC > 750/mm3
- •Platelet count ≥ 75,000/mm3
- •Hemoglobin ≥ 9.0 g/dl
- •INR and PTT normal
排除标准
- •Candidates will be ineligible for enrollment in the study if any of the following conditions apply:
- •Any biopsy-proven HSIL partially outside of the ETZ (for example, an HSIL lesion with extension to the perianal skin)
- •Any condylomas in the eligible treatment zone > 1/2 cm diameter
- •Note: Condylomas in the eligible treatment zone < 1/2 cm in diameter must be excised or cauterized (not treated topically) before or during Visit 1 (0 month RFA visit)
- •Any anal or rectal pathology requiring treatment including ulcer, fistula, fissure, or proctitis
- •Any anal stricture or stenosis in patient history or upon examination.
- •Symptomatic scarring in anal canal (i.e. not pliable, hyperkeratosis)
- •History of or present anal or rectal cancer
- •History of pelvic radiation therapy
- •History of HPV vaccination or plans to initiate HPV vaccination during the trial
- •History of ablation or resection therapy within the ETZ within 6 months prior to the 0 month RFA visit (other than cauterization or excision of condyloma(s))
- •Prior ablation or resection therapy consisting of ≥ 75% circumference within the ETZ of anal canal.
- •History of topical therapy (e.g. Imiquimod, 5-FU, Trichloroacetic acid) within the ETZ within 3 months prior to the 0 month RFA visit
- •Hemorrhoids > grade III
- •Fecal incontinence
- •Concurrent disease requiring systemic immunosuppression therapy
- •Concurrent malignancy requiring systemic therapy
- •Life expectancy < 2 years
- •Subject is on a platelet inhibiting agent (i.e. Aspirin, Clopidogrel, NSAIDS) and/or anti-thrombotic agent (Heparin, Warfarin) and unable to discontinue 7 days before and after treatment for 14 days total.
- •Exception: Aspirin 81 mg PO daily does not need to be discontinued
研究组 & 干预措施
Radiofrequency Ablation
Experimental
circumferential radiofrequency ablation (RFA) to the anal canal
干预措施: Radiofrequency Ablation (Barrx™) (Device)
结局指标
主要结局
Related Adverse Events
时间窗: Within 12 months post RFA
Adverse event : Device relationship - Definite, Probable, Possible
次要结局
- Quality of Life Assessment: Subject Score for Worry About Anal Canal Condition(0-2 weeks Prior RFA and after 9-12 months post RFA)
- Subject Tolerability: Post -Ablation Anal Pain(within 4 weeks post RFA)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal WandHSIL, High Grade Squamous Intraepithelial LesionsAin IIIAnal CancerHPV-Related Squamous Cell CarcinomaHuman Papilloma VirusHuman Papillomavirus InfectionNCT03302858Stephen E. Goldstone70
尚未招募
不适用
A Prospective Clinical Study on the Safety and Efficacy of Radiofrequency Ablation for the Treatment of Patients With Desmoid TumorsDesmoid TumorDesmoid FibromatosisDesmoidNCT06355921Blokhin's Russian Cancer Research Center27
招募中
2 期
Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract CancerBile Duct CancerNCT06274879Insel Gruppe AG, University Hospital Bern36
已完成
4 期
SMART China, A Multi-center Clinical Registry StudyAtrial FibrillationNCT02485925Biosense Webster, Inc.200
Unknown
不适用
Radiofrequency Ablation of Malignant Pulmonary NodulesCarcinomaNeoplasmsNCT02629978Chinese PLA General Hospital500